The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback